- Opinion
- [Reporter's View] Covid-19, endemic is not 'The End'
- by Eo, Yun-Ho Dec 6, 2023 06:00am
- ‘Endemic’ doesn’t mean THE END. Covid-19 has transitioned to an endemic after a long-fight against the virus for three years. Accordingly, each country is making an adjustment to the health protocol in a bid to meet domestic needs. The Korean government had announced that it will work to list Covid-19 treatments for reimbursement within t
- Opinion
- [Desk’s View] On resolving the stock shortage of drugs
- by Lee, Tak-Sun Dec 5, 2023 05:49am
- As a parent, I feel like I've been visiting hospitals after the endemic than I did during the COVID-19 pandemic. At the height of the pandemic, I only had to worry about COVID-19, but after the pandemic has passed, children with weak immunity are suffering from various viral diseases including colds, flu, and adenovirus. When my older daught
- Opinion
- [Reporter's View] Non-face-to-face treatment pilot project
- by Lee, Jeong-Hwan Dec 4, 2023 05:12am
- Starting December 15th, ’24-hour non-face-to-face treatment’ will be available to the public following the legalization of revised non-face-to-face treatment pilot project by the Ministry of Health and Welfare. The project will extend the non-fact-to-face treatment benefit that had been previously limited to returning patients to new pat
- Opinion
- [Reporter’s View] 1 yr after Zerbaxa's release
- by Eo, Yun-Ho Nov 20, 2023 05:50am
- One year has passed since the new antibiotic ‘Zerbaxa’ has been listed for reimbursement in Korea. At the time, the drug was applied the special exemption of the pharmacoeconomic evaluation system as a National Essential Medicine. The government’s flexible response amid the rise of the global issue of antimicrobial resistance shone thr
- Opinion
- [Reporter’s View]Encouraging healthy competition in NSCLC
- by Son, Hyung-Min Nov 16, 2023 05:46am
- Although it might be frustrating for those competing against each other, healthy competition often leads to beneficial results on the whole. This is the case for the EGFR-mutated non-small-cell lung cancer treatments, Yuhan Corp’s Leclaza (lasertinib) and AstraZeneca’s ‘Tagrisso (osimiertinib).’ Both drugs are third-generation tyrosin
- Opinion
- [Reporter’s view] Successive large-scale technology exports
- by Kim, Jin-Gu Nov 10, 2023 05:19am
- There is some good news coming from the pharmaceutical and bio industry. Chong Kun Dang and Orum Therapeutics have signed large-scale technology export contracts with global pharmaceutical companies. On the 6th, Chong Kun Dang signed a technology export contract with Novartis worth a total of $1.305 billion (about 1.7 trillion won). This is
- Opinion
- [Reporter's view] Preferential pharmaceutical alternative
- by Lee, Jeong-Hwan Nov 7, 2023 05:34am
- The government appears to be slow to announce a plan to reform the drug pricing system, which includes measures to give preferential prices for drugs that reflect the value of innovation. Although we have already held several consultative meetings with representatives of domestic and foreign pharmaceutical and biopharmaceutical companies, it
- Opinion
- [Reporter’s view] WLA Registration
- by Lee, Hye-Kyung Nov 3, 2023 05:32am
- WHO announced on October 26 that the Ministry of Food and Drug Safety was listed on the WHO Listed Authorities. The news became known in Korea on the afternoon of the 30th, when WHO posted a list of WLA-registered countries on its website and then suddenly deleted it. It was confirmed that the error was due to detailed coordination, and it w
- Opinion
- [Reporter’s View] Asthma drugs reimb through diff tracks
- by Eo, Yun-Ho Oct 25, 2023 05:24am
- An unusual case has emerged where drugs for the same indication were listed through different tracks for reimbursement in Korea. The interleukin-5 antagonists for asthma, ‘Cinquair (reslizumab)’ and GSK Korea’s ‘Nucala (mepolizumab)’ have been simultaneously listed for reimbursement in Korea through different reimbursement tracks. Ci
- Opinion
- [Reporter's view]Skill is more important than trends
- by Oct 20, 2023 05:31am
- Recently, antibody-drug conjugates (ADCs) have emerged rapidly in the pharmaceutical industry. ADC is a biopharmaceutical that combines an antibody that binds to a specific target antigen on the surface of cancer cells and a drug (payload) with a powerful cell-killing function. Unlike Roche Kadcyla, which is classified as a first-generati
